LRP4 sirna

LRP4 siRNA (Human)

Cat. Num. AAA8201240

• Gene Names: LRP4; CLSS; CMS17; LRP-4; LRP10; MEGF7; SOST2
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: LRP4; LRP4 siRNA (Human); KIAA0816; LRP10; MEGF7; Low-density lipoprotein receptor-related protein 4; LRP-4; Multiple epidermal growth factor-like domains 7; LRP4 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: LRP4 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1,905

• Applicable Applications for LRP4 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human LRP4 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for LRP4 sirna

siRNA to inhibit LRP4 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 157384998
• NCBI GeneID: 4038
• NCBI Accession #: NP_002325.2
• NCBI GenBank Nucleotide #: NM_002334.3
• UniProt Accession #: O75096; Q4AC85; Q5KTZ5; B2RN39
• Molecular Weight: 212,045 Da
• NCBI Official Full Name: low-density lipoprotein receptor-related protein 4
• NCBI Official Synonym Full Names: low density lipoprotein receptor-related protein 4
• NCBI Official Symbol: LRP4
• NCBI Official Synonym Symbols: CLSS; CMS17; LRP-4; LRP10; MEGF7; SOST2
• NCBI Protein Information: low-density lipoprotein receptor-related protein 4
• UniProt Protein Name: Low-density lipoprotein receptor-related protein 4
• Protein Family: Low-density lipoprotein receptor-related protein
• UniProt Gene Name: LRP4
• UniProt Synonym Gene Names: KIAA0816; LRP10; MEGF7; LRP-4
• UniProt Entry Name: LRP4_HUMAN

NCBI Description

This gene encodes a member of the low-density lipoprotein receptor-related protein family. The encoded protein may be a regulator of Wnt signaling. Mutations in this gene are associated with Cenani-Lenz syndrome. [provided by RefSeq, May 2010]

Uniprot Description

LRP4: Mediates SOST-dependent inhibition of bone formation. Functions as a specific facilitator of SOST-mediated inhibition of Wnt signaling. Plays a key role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between motor neuron and skeletal muscle. Directly binds AGRIN and recruits it to the MUSK signaling complex. Mediates the AGRIN- induced phosphorylation of MUSK, the kinase of the complex. The activation of MUSK in myotubes induces the formation of NMJ by regulating different processes including the transcription of specific genes and the clustering of AChR in the postsynaptic membrane. Alternatively, may be involved in the negative regulation of the canonical Wnt signaling pathway, being able to antagonize the LRP6-mediated activation of this pathway. More generally, has been proposed to function as a cell surface endocytic receptor binding and internalizing extracellular ligands for degradation by lysosomes. Defects in LRP4 are the cause of Cenani-Lenz syndactyly syndrome (CLSS). It is a congenital malformation syndrome defined as complete and complex syndactyly of the hands combined with malformations of the forearm bones and similar manifestations in the lower limbs. Defects in LRP4 are the cause of sclerosteosis type 2 (SOST2). A sclerosing bone dysplasia characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients. Belongs to the LDLR family.

Protein type: Membrane protein, integral; Cell surface; Receptor, misc.

Chromosomal Location of Human Ortholog: 11p11.2

Cellular Component: cell surface; cell soma; postsynaptic density; dendrite; integral to membrane; flotillin complex; neuromuscular junction

Molecular Function: protein binding; protein homodimerization activity; apolipoprotein binding; calcium ion binding; receptor tyrosine kinase binding

Biological Process: limb development; extracellular matrix organization and biogenesis; regulation of protein amino acid phosphorylation; Wnt receptor signaling pathway; dendrite morphogenesis; endocytosis; odontogenesis of dentine-containing teeth; dorsal/ventral pattern formation; synaptic growth at neuromuscular junction; hair follicle development; synapse organization and biogenesis; negative regulation of ossification; protein heterotetramerization; negative regulation of axonogenesis; embryonic digit morphogenesis; kidney development; proximal/distal pattern formation

Disease: Myasthenic Syndrome, Congenital, 17; Cenani-lenz Syndactyly Syndrome; Sclerosteosis 2